Multiple Sclerosis Treatment with Adult Stem Cells
by David Prentice
December 14, 2009
The latest success story comes from Australia. Ben Leahy, 20, was in a wheelchair and experiencing vision problems when he was treated earlier in 2009. Ben is now walking after treatment with adult stem cells. The treatment involves isolating the patient’s bone marrow adult stem cells, giving the patient mild chemotherapy to destroy the rogue immune cells that are attacking the nervous system, then re-injecting the patient’s adult stem cells.
While the Australian group has not yet published their results, the technique mirrors the treatment results published in 2009 in Lancet Neurology by Dr. Richard Burt’s team at Northwestern, where they reported that they had reversed the neurological dysfunction of early-stage multiple sclerosis patients. As Dr. Burt noted:
“This is the first time we have turned the tide on this disease.”
The group is now engaged in a larger, randomized clinical trial for multiple sclerosis.
Edwin McClure was treated with his own adult stem cells for MS.
In a previous clinical review published in the Journal of the American Medical Association in 2008, the evidence indicated that adult stem cells were showing success for many diseases, including multiple sclerosis.
Barry Goudy is one of the MS patients who was helped by adult stem cell treatment.
Dr. Mark Freedman of the University of Ottawa has also reported similar success treating MS patients.
Burt and Voltarelli have also published successful results treating patients for other autoimmune diseases, including type I (juvenile) diabetes.
Family Research Council is a 501c(3) non-profit organization. If this post has been helpful to you, please consider a gift to help us continue to advance Faith, Family, and Freedom.
Comments
[...] Read more: FRC Blog » Multiple Sclerosis Treatment with Adult Stem Cells [...]
[...] original here: FRC Blog » Multiple Sclerosis Treatment with Adult Stem Cells By admin | category: treatment | tags: are-attacking, involves-isolating, [...]
I’m a chronic progressive, and have not, unfortunately, experienced any substantial benefit from LDN.
The causes, course of this disorder are many, and a one-size-fits-all treatment remains elusive.
I agree. The sooner this is investigated, the sooner questions can be answered.
Penny, I don’t know how long you’ve been taking LDN, but I do know not all experience benefits. Of those who do, it can sometimes take 6 months or more.
I’m sorry you haven’t experienced any benefit yet. One of the many LDN patient support networks may help, beginning with the Yahoo lowdosenaltrexone group which has many long-term members with years of experience in MS & LDN.
The first and complete book on heart failure and adult stem cells is in my library. It was written by author/researcher Christian Wilde and is called, Miracle Stem Cell Heart Repair. Actual patient stories and heart scans before and after. Also Edwin McClure’s wonderful success story beating MS is in the Wilde Stem Cell Research Report.
Does this works also for progressive MS ?
I bought and read a book on LDN as it applied to many illnesses, including MS. For MS, the improvements seemed to be consistent with the placebo effect. Perhaps there are different possible avenues of cure/improvement and LDN addresses some. Certainly, there were at least 50% non-improvement cases. We might have tried it but my wife’s chronic progressive quadriplegia is too painful to cease painkillers for the duration of the trial.
By: Cris Kerr | December 14, 2009 at 4:26 pm
I don’t understand… everyone can write about MS treatments that have not been proven effective over extended periods of time for all forms of MS, yet will not write of treatments that patients themselves say have been effective for them over extended periods of time… and importantly, not just for Relapsing Remitting MS but also progressive forms of MS and other immune system diseases.
The free ebook ‘Those Who Suffer Much, Know Much’ available from LDN Research Trust in the UK contains 29 MS success stories presented as patient case studies. The book features a treatment patients themselves say is working for them, low doses of naltrexone (LDN)… or in other words, extremely low doses of an old drug with a good safety profile but unfortunately, unlike stem cells, one that happens to be long out-of-patent.
Understandably, with no profit potential the health industry has expressed zero interest in trialling this treatment, but even our health authorities are ignoring the potential of this lower cost, lower risk treatment.
This response may well be deleted as many have been before, but at least one more person will now be LDNAware.
(1) PILOT TRIAL NEWS – 1: Mult Scler. 2008 Sep;14(8):1076-83
A pilot trial of low-dose naltrexone in primary progressive multiple
sclerosis.
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M,
Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi
M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G.
Institute of Experimental Neurology (INSPE) and Department of Neurology,
San Raffaele Scientific Institute, Via Olgettina 58, Milan, Italy;
Fondazione Don Carlo Gnocchi, IRCCS, Milan, Italy.
A sixth month phase II multicenter-pilot trial with a low dose of the
opiate antagonist Naltrexone (LDN) has been carried out in 40 patients with
primary progressive multiple sclerosis (PPMS).
The primary end points were safety and tolerability.
Secondary outcomes were efficacy on spasticity, pain, fatigue, depression,
and quality of life. Clinical and biochemical evaluations were serially
performed. Protein concentration of beta-endorphins (BE) and mRNA levels
and allelic variants of the mu-opiod receptor gene (OPRM1) were analyzed.
Five dropouts and two major adverse events occurred. The remaining adverse
events did not interfere with daily living. Neurological disability
progressed in only one patient.
A significant reduction of spasticity was measured at the end of the trial.
BE concentration increased during the trial, but no association was found
between OPRM1 variants and improvement of spasticity. Our data clearly
indicate that LDN is safe and well tolerated in patients with PPMS.
PMID: 18728058 PubMed – in process
http://www.ncbi.nlm.nih.gov/pubmed/18728058